Table 3 Antihypertensive & hypoglycemic Agents among study participants at JUMC, 2017
Medications | Frequency | Percentage |
|---|---|---|
1. Antihypertensive agents | ||
Monotherapy | 31 | 23.66 |
 Enalapril | 14 | 10.68 |
 Amlodipine | 9 | 6.87 |
 Nifedipine | 4 | 3.05 |
 Hydrochlorothiazide | 3 | 2.29 |
 Atenolol | 1 | 0.76 |
Dual therapy | 89 | 67.94 |
 Hydrochlorothiazide + Enalapril | 23 | 17.55 |
 Hydrochlorothiazide + Atenolol | 7 | 5.34 |
 Enalapril + Amlodipine | 43 | 32.82 |
 Atenolol + Amlodipine | 2 | 1.53 |
 Enalapril + Atenolol | 12 | 9.16 |
 Losartan +Amlodipine | 2 | 1.53 |
Triple Therapy | 11 | 8.40 |
 Hydrochlorothiazide + Enalapril + Amlodipine | 5 | 3.82 |
 Furosemide + Enalapril +Amlodipine | 2 | 1.53 |
 Metoprolol + Enalapril + Furosemide | 4 | 3.05 |
2. Antidiabetic agents | ||
 Insulin | 59 | 45.04 |
 Oral hypoglycemic | 45 | 34.35 |
 Insulin + Oral hypoglycemic | 27 | 20.61 |